These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38237604)

  • 21. Single- and Multiple-Dose Study To Determine the Safety, Tolerability, Pharmacokinetics, and Food Effect of Oral MRX-I versus Linezolid in Healthy Adult Subjects.
    Eckburg PB; Ge Y; Hafkin B
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167545
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of ultra-performance liquid chromatography-tandem mass spectrometric methods for simultaneous and rapid determination of contezolid and its major metabolite M2 in plasma and urine samples and its application to a study in subjects with moderate liver impairment.
    Wang Y; Wu H; Wu J; Fan Y; Liu X; Li Y; Hu J; Zhang J; Guo B
    J Chromatogr B Analyt Technol Biomed Life Sci; 2022 Feb; 1191():123129. PubMed ID: 35066246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Pharmacology and Utility of Contezolid in Chinese Patients with Complicated Skin and Soft-Tissue Infections.
    Yuan H; Wu H; Zhang Y; Huang H; Li Y; Wu J; Cao G; Yu J; Guo B; Wu J; Yuan Z; Chen Y; Yang W; Wu X; Zhang J
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0243021. PubMed ID: 35575579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospects of contezolid (MRX-I) against multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis.
    Yang M; Zhan S; Fu L; Wang Y; Zhang P; Deng G
    Drug Discov Ther; 2022 May; 16(2):99-101. PubMed ID: 35418550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contezolid for the Treatment of Drug-Resistant Tuberculosis in China: A Clinical Case Series.
    Xiong YJ; Xiao Y; Xie L; Gao L; Han Y; Huang PF; Liu S; Liang YX; Wang H
    Infect Drug Resist; 2024; 17():3491-3499. PubMed ID: 39157746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concentration of contezolid in cerebrospinal fluid and serum in a patient with tuberculous meningoencephalitis: A case report.
    Guo W; Hu M; Xu N; Shangguan Y; Xia J; Hu W; Li X; Zhao Q; Xu K
    Int J Antimicrob Agents; 2023 Aug; 62(2):106875. PubMed ID: 37276894
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
    Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Novel Oxazolidinone TBI-223 Is Effective in Three Preclinical Mouse Models of Methicillin-Resistant Staphylococcus aureus Infection.
    Gordon O; Dikeman DA; Ortines RV; Wang Y; Youn C; Mumtaz M; Orlando N; Zhang J; Patel AM; Gough E; Kaushik A; Nuermberger EL; Upton AM; Fotouhi N; Miller LS; Archer NK
    Microbiol Spectr; 2022 Oct; 10(5):e0245121. PubMed ID: 36106881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concentration-response modeling of ECG data from early-phase clinical studies to assess QT prolongation risk of contezolid (MRX-I), an oxazolidinone antibacterial agent.
    Wu J; Wang K; Chen Y; Yuan H; Li L; Zhang J
    J Pharmacokinet Pharmacodyn; 2019 Dec; 46(6):531-541. PubMed ID: 31410633
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-term Safety, Tolerability, and Pharmacokinetics of MRX-I, an Oxazolidinone Antibacterial Agent, in Healthy Chinese Subjects.
    Wu X; Li Y; Zhang J; Zhang Y; Yu J; Cao G; Chen Y; Guo B; Shi Y; Huang J; Cao Y; Liu X; Wu J; Gordeev MF; Yuan H; Wang W
    Clin Ther; 2018 Feb; 40(2):322-332.e5. PubMed ID: 29398160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Oxazolidinones for Tuberculosis: Are Novel Treatments on the Horizon?
    Chen RH; Burke A; Cho JG; Alffenaar JW; Davies Forsman L
    Pharmaceutics; 2024 Jun; 16(6):. PubMed ID: 38931939
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    An H; Sun W; Liu X; Wang T; Qiao J; Liang J
    Microbiol Spectr; 2023 Sep; 11(5):e0462722. PubMed ID: 37732805
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oxazolidinone: A promising scaffold for the development of antibacterial drugs.
    Yuan S; Shen DD; Bai YR; Zhang M; Zhou T; Sun C; Zhou L; Wang SQ; Liu HM
    Eur J Med Chem; 2023 Mar; 250():115239. PubMed ID: 36893700
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Utility of Contezolid-Containing Regimens in 25 Cases of Linezolid-Intolerable Tuberculosis Patients.
    Wang J; Nie W; Ma L; Li Q; Geng R; Shi W; Chu N
    Infect Drug Resist; 2023; 16():6237-6245. PubMed ID: 37745897
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Wang S; Cai C; Shen Y; Sun C; Shi Q; Wu N; Zheng S; Qian J; Zhang R; Zhou H
    Front Microbiol; 2021; 12():729900. PubMed ID: 34489919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case report: Successful treatment with contezolid in a patient with tuberculous meningitis who was intolerant to linezolid.
    Xu Z; Zhang J; Guan T; Wan G; Jiang C; Lang L; Wang L
    Front Med (Lausanne); 2023; 10():1224179. PubMed ID: 37928457
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs.
    Knight EV; Kimball JP; Keenan CM; Smith IL; Wong FA; Barrett DS; Dempster AM; Lieuallen WG; Panigrahi D; Powers WJ; Szot RJ
    Fundam Appl Toxicol; 1996 Sep; 33(1):38-48. PubMed ID: 8812216
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reversible and Species-Specific Depigmentation Effects of AZD3293, a BACE Inhibitor for the Treatment of Alzheimer's Disease, Are Related to BACE2 Inhibition and Confined to Epidermis and Hair.
    Cebers G; Lejeune T; Attalla B; Soderberg M; Alexander RC; Budd Haeberlein S; Kugler AR; Ingersoll EW; Platz S; Scott CW
    J Prev Alzheimers Dis; 2016; 3(4):202-218. PubMed ID: 29199322
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sixty-day repeated dose toxicity of sinafloxacin in rats and dogs.
    Lu GC; She JH; Jiang H; Li ZY; Yuan BJ
    Food Chem Toxicol; 2008 Feb; 46(2):575-80. PubMed ID: 17942207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rare tuberculosis in recipients of allogeneic hematopoietic stem cell transplantation successfully treated with contezolid-a typical case report and literature review.
    Li J; Yu Z; Jiang Y; Lao S; Li D
    Front Cell Infect Microbiol; 2023; 13():1258561. PubMed ID: 37908760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.